Pulmonary Arterial Hypertension Market Size, Trends, Analysis, and Outlook By Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors. Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), by Region, Country, Segment, and Companies, 2024-2030
The global Pulmonary Arterial Hypertension market size is poised to register 5.93% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Pulmonary Arterial Hypertension market across By Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors. Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational).
The Pulmonary Arterial Hypertension (PAH) market is witnessing steady growth due to advancements in treatment options, improved diagnostic techniques, and increased awareness about the disease. PAH is a progressive condition characterized by elevated blood pressure in the arteries of the lungs, leading to symptoms such as shortness of breath, fatigue, and chest pain. Factors such as the development of targeted therapies, including prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, and the expansion of combination therapy approaches are driving market expansion. Additionally, advancements in diagnostic imaging modalities, such as echocardiography and right heart catheterization, along with the integration of biomarker testing and risk stratification algorithms, are fueling innovation in the market. Moreover, the increasing prevalence of risk factors for PAH, such as connective tissue diseases and congenital heart defects, the expansion of specialized PAH treatment centers and expert referral networks, and the rising investments in PAH-specific drug development and clinical research are driving market growth. Furthermore, efforts to improve early detection, optimize treatment strategies, and enhance patient outcomes through multidisciplinary care approaches are expected to further propel market growth in the foreseeable future.
Pulmonary Arterial Hypertension Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Pulmonary Arterial Hypertension market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Pulmonary Arterial Hypertension survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Pulmonary Arterial Hypertension industry.
Key market trends defining the global Pulmonary Arterial Hypertension demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Pulmonary Arterial Hypertension Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Pulmonary Arterial Hypertension industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Pulmonary Arterial Hypertension companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Pulmonary Arterial Hypertension industry
Leading Pulmonary Arterial Hypertension companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Pulmonary Arterial Hypertension companies.
Pulmonary Arterial Hypertension Market Study- Strategic Analysis Review
The Pulmonary Arterial Hypertension market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Pulmonary Arterial Hypertension industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Pulmonary Arterial Hypertension Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Pulmonary Arterial Hypertension Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Pulmonary Arterial Hypertension market segments. Similarly, Strong end-user demand is encouraging Canadian Pulmonary Arterial Hypertension companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Pulmonary Arterial Hypertension market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Pulmonary Arterial Hypertension Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Pulmonary Arterial Hypertension industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Pulmonary Arterial Hypertension market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Pulmonary Arterial Hypertension Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Pulmonary Arterial Hypertension in Asia Pacific. In particular, China, India, and South East Asian Pulmonary Arterial Hypertension markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Pulmonary Arterial Hypertension Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Pulmonary Arterial Hypertension Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Pulmonary Arterial Hypertension market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension Market Company Profiles
The global Pulmonary Arterial Hypertension market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Viatris Inc.
Recent Pulmonary Arterial Hypertension Market Developments
The global Pulmonary Arterial Hypertension market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Pulmonary Arterial Hypertension Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Class
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
By Type
Branded
Generics
By Route of Administration
Oral
Intravenous/ subcutaneous
Inhalational
Geographical Segmentation:
Bayer
Gilead Sciences, Inc.
GlaxoSmithKline
Johnson & Johnson
Lupin Pharmaceuticals, Inc.
Sandoz Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Viatris Inc.
Formats Available: Excel, PDF, and PPT
The Pulmonary Arterial Hypertension (PAH) market is witnessing steady growth due to advancements in treatment options, improved diagnostic techniques, and increased awareness about the disease. PAH is a progressive condition characterized by elevated blood pressure in the arteries of the lungs, leading to symptoms such as shortness of breath, fatigue, and chest pain. Factors such as the development of targeted therapies, including prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors, and the expansion of combination therapy approaches are driving market expansion. Additionally, advancements in diagnostic imaging modalities, such as echocardiography and right heart catheterization, along with the integration of biomarker testing and risk stratification algorithms, are fueling innovation in the market. Moreover, the increasing prevalence of risk factors for PAH, such as connective tissue diseases and congenital heart defects, the expansion of specialized PAH treatment centers and expert referral networks, and the rising investments in PAH-specific drug development and clinical research are driving market growth. Furthermore, efforts to improve early detection, optimize treatment strategies, and enhance patient outcomes through multidisciplinary care approaches are expected to further propel market growth in the foreseeable future.
Pulmonary Arterial Hypertension Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Pulmonary Arterial Hypertension market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Pulmonary Arterial Hypertension survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Pulmonary Arterial Hypertension industry.
Key market trends defining the global Pulmonary Arterial Hypertension demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Pulmonary Arterial Hypertension Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Pulmonary Arterial Hypertension industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Pulmonary Arterial Hypertension companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Pulmonary Arterial Hypertension industry
Leading Pulmonary Arterial Hypertension companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Pulmonary Arterial Hypertension companies.
Pulmonary Arterial Hypertension Market Study- Strategic Analysis Review
The Pulmonary Arterial Hypertension market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Pulmonary Arterial Hypertension industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Pulmonary Arterial Hypertension Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Pulmonary Arterial Hypertension Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Pulmonary Arterial Hypertension market segments. Similarly, Strong end-user demand is encouraging Canadian Pulmonary Arterial Hypertension companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Pulmonary Arterial Hypertension market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Pulmonary Arterial Hypertension Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Pulmonary Arterial Hypertension industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Pulmonary Arterial Hypertension market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Pulmonary Arterial Hypertension Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Pulmonary Arterial Hypertension in Asia Pacific. In particular, China, India, and South East Asian Pulmonary Arterial Hypertension markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Pulmonary Arterial Hypertension Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Pulmonary Arterial Hypertension Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Pulmonary Arterial Hypertension market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension Market Company Profiles
The global Pulmonary Arterial Hypertension market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, Viatris Inc.
Recent Pulmonary Arterial Hypertension Market Developments
The global Pulmonary Arterial Hypertension market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Pulmonary Arterial Hypertension Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Class
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
By Type
Branded
Generics
By Route of Administration
Oral
Intravenous/ subcutaneous
Inhalational
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Bayer
Gilead Sciences, Inc.
GlaxoSmithKline
Johnson & Johnson
Lupin Pharmaceuticals, Inc.
Sandoz Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Viatris Inc.
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Pulmonary Arterial Hypertension Market Overview and Key Findings, 2024
1.2 Pulmonary Arterial Hypertension Market Size and Growth Outlook, 2021- 2030
1.3 Pulmonary Arterial Hypertension Market Growth Opportunities to 2030
1.4 Key Pulmonary Arterial Hypertension Market Trends and Challenges
1.4.1 Pulmonary Arterial Hypertension Market Drivers and Trends
1.4.2 Pulmonary Arterial Hypertension Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Pulmonary Arterial Hypertension Companies
2. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE OUTLOOK TO 2030
2.1 Pulmonary Arterial Hypertension Market Size Outlook, USD Million, 2021- 2030
2.2 Pulmonary Arterial Hypertension Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. PULMONARY ARTERIAL HYPERTENSION MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Class
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
By Type
Branded
Generics
By Route of Administration
Oral
Intravenous/ subcutaneous
Inhalational
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Pulmonary Arterial Hypertension Market, 2025
5.2 Asia Pacific Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Pulmonary Arterial Hypertension Market, 2025
5.5 Europe Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.6 Europe Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Pulmonary Arterial Hypertension Market, 2025
5.8 North America Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.9 North America Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Pulmonary Arterial Hypertension Market, 2025
5.11 South America Pacific Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.12 South America Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Pulmonary Arterial Hypertension Market, 2025
5.14 Middle East Africa Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Pulmonary Arterial Hypertension Market Size Outlook and Revenue Growth Forecasts
6.2 US Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Pulmonary Arterial Hypertension Industry Drivers and Opportunities
7. PULMONARY ARTERIAL HYPERTENSION MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. PULMONARY ARTERIAL HYPERTENSION COMPANY PROFILES
8.1 Profiles of Leading Pulmonary Arterial Hypertension Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Bayer
Gilead Sciences, Inc.
GlaxoSmithKline
Johnson & Johnson
Lupin Pharmaceuticals, Inc.
Sandoz Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Viatris Inc.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Pulmonary Arterial Hypertension Market Overview and Key Findings, 2024
1.2 Pulmonary Arterial Hypertension Market Size and Growth Outlook, 2021- 2030
1.3 Pulmonary Arterial Hypertension Market Growth Opportunities to 2030
1.4 Key Pulmonary Arterial Hypertension Market Trends and Challenges
1.4.1 Pulmonary Arterial Hypertension Market Drivers and Trends
1.4.2 Pulmonary Arterial Hypertension Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Pulmonary Arterial Hypertension Companies
2. PULMONARY ARTERIAL HYPERTENSION MARKET SIZE OUTLOOK TO 2030
2.1 Pulmonary Arterial Hypertension Market Size Outlook, USD Million, 2021- 2030
2.2 Pulmonary Arterial Hypertension Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. PULMONARY ARTERIAL HYPERTENSION MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. PULMONARY ARTERIAL HYPERTENSION MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Class
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
By Type
Branded
Generics
By Route of Administration
Oral
Intravenous/ subcutaneous
Inhalational
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Pulmonary Arterial Hypertension Market, 2025
5.2 Asia Pacific Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Pulmonary Arterial Hypertension Market, 2025
5.5 Europe Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.6 Europe Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Pulmonary Arterial Hypertension Market, 2025
5.8 North America Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.9 North America Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Pulmonary Arterial Hypertension Market, 2025
5.11 South America Pacific Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.12 South America Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Pulmonary Arterial Hypertension Market, 2025
5.14 Middle East Africa Pulmonary Arterial Hypertension Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Pulmonary Arterial Hypertension Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Pulmonary Arterial Hypertension Market Size Outlook and Revenue Growth Forecasts
6.2 US Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Pulmonary Arterial Hypertension Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Pulmonary Arterial Hypertension Industry Drivers and Opportunities
7. PULMONARY ARTERIAL HYPERTENSION MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. PULMONARY ARTERIAL HYPERTENSION COMPANY PROFILES
8.1 Profiles of Leading Pulmonary Arterial Hypertension Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Bayer
Gilead Sciences, Inc.
GlaxoSmithKline
Johnson & Johnson
Lupin Pharmaceuticals, Inc.
Sandoz Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Viatris Inc.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
